Celsion (NASDAQ:CLSN) Announces Earnings Results, Beats Estimates By $0.04 EPS
Celsion (NASDAQ:CLSN) issued its quarterly earnings results on Wednesday. The biotechnology company reported ($0.29) EPS for the quarter, beating analysts’ consensus estimates of ($0.33) by $0.04, Fidelity Earnings reports. The firm had revenue of $0.13 million during the quarter, compared to the consensus estimate of $0.13 million. Celsion had a negative return on equity of 65.35% and a negative net margin of 1,954.60%.
CLSN traded up $0.01 on Thursday, reaching $1.70. The company’s stock had a trading volume of 1,078 shares, compared to its average volume of 91,435. The firm has a market cap of $34.61 million, a PE ratio of -2.50 and a beta of 1.94. Celsion has a 1 year low of $1.35 and a 1 year high of $3.10. The company has a debt-to-equity ratio of 0.51, a quick ratio of 4.22 and a current ratio of 4.22. The firm has a 50 day moving average of $1.75.
A number of research analysts recently commented on the company. ValuEngine raised Celsion from a “sell” rating to a “hold” rating in a report on Thursday, August 1st. Brookline Capital Management reissued a “buy” rating on shares of Celsion in a report on Thursday, July 25th. Finally, Zacks Investment Research raised Celsion from a “sell” rating to a “hold” rating in a report on Tuesday, July 16th.
Celsion Corporation, a development stage oncology drug company, focuses on the development and commercialization of directed chemotherapies, DNA-mediated immunotherapy, and RNA based therapies for the treatment of cancer. Its lead product candidate is ThermoDox, a liposomal encapsulation of doxorubicin that is in Phase III clinical trial for treating primary liver cancer.
Receive News & Ratings for Celsion Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Celsion and related companies with MarketBeat.com's FREE daily email newsletter.